Loading clinical trials...

Norms and Validation for IntelliSpace Cognition Spanish Version | Clinical Trials | Clareo Health

COMPLETED

Norms and Validation for IntelliSpace Cognition Spanish Version

NCT05210777•Philips Electronics Nederland B.V. acting through Philips CTO organization

Summary

This study aims to validate and provide applicable norms for the United States (US) Spanish versions of the IntelliSpace Cognition (ISC) neuropsychological tests.

Detailed Description

The study will collect test scores from the Spanish speaking Hispanic US population for Spanish translations/adaptations of the ISC tests with the aim to assess how the Spanish language version of ISC tests compare to the English language version of ISC tests, and to create norms for the Spanish language version of the tests.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Self-reported:
•Participant is 18 years or older.
•Participant considers herself or himself to be Hispanic/Latino.
•Participant has Spanish as their primary and dominant language, or reports speaking Spanish as equally as good as she or he speaks English.
•Participant is able to see well (naturally or corrected by means of eyeglasses or lenses).
•Participant is able to hear well (naturally or corrected by means of a hearing aid).
•Participant is able to use their fingers, hands and arms to write symbols.
•Participant has valid health insurance.
•Investigator observed:
•Participant is able to give informed consent.
+2 more criteria

Exclusion Criteria

•Self-reported:
•Participant has participated in previous studies where IntelliSpace Cognition was used (PJ-011726: "Study to establish the psychometric properties of the digital cognitive tests on the Philips IntelliSpace Cognition Platform" conducted during 2019 or ICBE-S-000233: "Norms Expansion and Validation for IntelliSpace Cognition" conducted during 2021).
•Participant is currently admitted to a hospital, assisted living, nursing home or a psychiatric facility.
•Participant is diagnosed with a neurological disorder or disease that may affect cognitive functioning (e.g., Parkinson's, brain tumor, stroke, Traumatic Brain Injury (TBI), epilepsy, encephalitis, dementia).
•Admissible: Epilepsy with no more than 2 seizures and not currently receiving epilepsy treatment and not currently seeking medical attention related to seizures.
•Participant is diagnosed with a language disorder or aphasia (expressive or mixed receptive/expressive).
•Admissible: Articulation disorder.
•Participant is diagnosed with a learning disorder.
•Participant is diagnosed with an autoimmune disorder that may affect cognitive functioning (e.g., LUPUS, Multiple Sclerosis).
•Participant is or was diagnosed with a current or past psychotic disorder (e.g., schizophrenia).
+33 more criteria

Locations (2)

suAzio

Hollywood, California, United States

suAzio

Hollywood, Florida, United States

Key Dates

Start Date

January 31, 2022

Primary Completion Date

April 15, 2022

Completion Date

May 19, 2022

Last Updated

July 18, 2022

Enrollment

ACTUAL participants

Conditions

Cognitive Functioning of Healthy IndividualsHispanic

Interventions

observation

DEVICE

Integrating Systems and Basic Income: Improving Outcomes for Families of Young Children

NCT07261254

IncomeInfant, Newborn+12 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 18, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions